Trial · NCT04735042
SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
NCT04735042, Completed, University of Pisa
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. Trials, record NCT04735042. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04735042
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
- NCT number
- NCT04735042
- Status
- Completed
- Enrollment
- 60 participants, actual
- Lead sponsor
- University of Pisa
- Conditions
- Type 2 Diabetes, Urinary Tract Infections
- Interventions
- Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill, Empagliflozin or Dapagliflozin Pill
- First posted
- 2021-02-02
- Last updated
- 2025-07-18
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in metagenomic analysis based on rRNA 16S gene | Each patients will be analyzed at baseline and after 12 weeks | Metagenomic analysis based on rRNA 16S gene will be performed by Novogene on Illumina platform (Hong Kong, China) |
| Primary | Change from Baseline of total bacterial load | Each patients will be analyzed at baseline and after 12 weeks | Absolute quantification of total bacterial load in the original sample using real-Time quantitative PCR |
| Secondary | Fasting glucose | baseline and 12 week | Fasting glucose measured in a fasting morning blood sample |
| Secondary | Glycated Haemoglobin | baseline and 12 week | HbA1c in a fasting measured in a morning blood sample |
| Secondary | Renal function | baseline and 12 week | Using creatinine measured in a fasting morning blood sample and estimated by eGFR (calculated with the CDK-EPI formula) |
| Secondary | Albumin excretion | baseline and 12 week | Measured by urinary albumin/creatinine ratio |
| Secondary | Total cholesterol | baseline and 12 week | Total cholesterol measured in a fasting morning blood sample |
| Secondary | HDL cholesterol | baseline and 12 week | HDL cholesterol measured in a fasting morning blood sample |
| Secondary | Triglycerides | baseline and 12 week | Triglycerides measured in a fasting morning blood sample |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04735042
GET https://conductscience.org/api/trials/v1/NCT04735042/registered